RNAM vs. ABBV

Last updated Jun 3, 2026

RNAM (Avidity Biosciences, Inc.) and ABBV (AbbVie Inc.) are both stocks. Both are in the Healthcare sector — RNAM in Biotechnology, ABBV in Drug Manufacturers - General.

Performance

RNAM vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Avidity Biosciences, Inc. (RNAM) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RNAM

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

ABBV

• 1D: 0.80%
• 1M: 4.31%
• YTD: -3.41%
• 6M: -4.15%
• 1Y: 19.73%
• 3Y*: 20.88%
• 5Y*: 18.44%
• 10Y*: 17.56%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RNAM vs. ABBV - Yearly Performance Comparison

	2026 (YTD)
RNAM Avidity Biosciences, Inc.	0.00%
ABBV AbbVie Inc.	-2.56%

Fundamentals

Market Cap RNAM : $10.87B ABBV : $385.19B
EPS RNAM : -$4.93 ABBV : $2.05
PS Ratio RNAM : 539.42 ABBV : 6.13
PB Ratio RNAM : 6.44 ABBV : 14.01
Total Revenue (TTM) RNAM : $18.76M ABBV : $62.82B
Gross Profit (TTM) RNAM : $14.60M ABBV : $46.15B
EBITDA (TTM) RNAM : -$741.79M ABBV : $17.96B

Return for Risk

RNAM vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABBV

ABBV Risk / Return Rank: 62
ABBV Sharpe Ratio Rank: 66
ABBV Sortino Ratio Rank: 60
ABBV Omega Ratio Rank: 59
ABBV Calmar Ratio Rank: 63
ABBV Martin Ratio Rank: 63

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RNAM vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Avidity Biosciences, Inc. (RNAM) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	RNAM	ABBV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.83	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.81	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.68	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.73	—

Drawdowns

Drawdown Indicators

	RNAM	ABBV	Difference
Max Drawdown Largest peak-to-trough decline	—	-45.09%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-17.32%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-20.74%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-21.92%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-45.09%	—
Current Drawdown Current decline from peak	—	-9.04%	—
Average Drawdown Average peak-to-trough decline	—	-10.73%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	7.69%	—

Volatility

Volatility by Period

	RNAM	ABBV	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	5.42%	—
Volatility (6M) Calculated over the trailing 6-month period	—	17.61%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	23.96%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	22.84%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	25.74%	—

Dividends

RNAM vs. ABBV - Dividend Comparison

RNAM has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.10%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ABBV AbbVie Inc.	3.10%	2.87%	3.49%	3.82%	3.49%	3.84%	4.41%	4.83%	3.89%	2.65%	3.64%	3.41%
RNAM Avidity Biosciences, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials